Atrial fibrillation ablation – Your questions answered: Part 2

   Rated 4.5 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0.5 hours

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 hours

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
0 hours

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

In this episode:

  • Oral antiarrhythmics have limited efficacy and significant risks
  • Catheter ablation is now a first-line option in suitable patients
  • Newer ablation technology – Pulsed field ablation (PFA) is safer and faster
  • Anticoagulation decisions remain based on stroke risk, not ablation status
  • Genuine post-procedural issues may be benign
  • Ongoing healthcare professional role – Blood pressure and risk factor control

 

The questions answered in this podcast are listed below.
They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars.

  1. How effective are oral antiarrhythmic medications?
  2. Does this cure atrial fibrillation?
  3. What is the current state of ablation technology?
  4. Can you explain what you mean by “rapid” and provide an example of how long a procedure typically takes?
  5. Does reduced scarring decrease the likelihood or complexity of needing a repeat ablation?
  6. What are some of the contraindications in terms of structurally abnormal heart that would be contraindications for the patient?
  7. How should atrial fibrillation be approached in patients with severe ischaemic heart disease? Does this complicate treatment?
  8. If a patient has an AF ablation, can they come off my anticoagulant?
  9. How do you manage patient’s embolic issues?
  10. How soon after the procedure can patients typically be discharged?
  11. Following successful AF suppression, is it possible for patients to stop taking DOACs or other anticoagulants?
  12. After discharge, how soon should patients follow up with their GP?
  13. What should the GP monitor and what should be communicated back to the specialist?
  14. When will you consider AV node ablation and insertion of a pacemaker?

 

Expert: Prof Rukshen Weerasooriya, Cardiac Electrophysiologist

Host: Dr David Lim, GP and Medical Educator

Total time: 44 mins

 

Recommended resources:

 

Last Updated: 1 Jul, 2025

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Gary Wittert

Prof Gary Wittert

The Peptide Craze – What You Need to Know

Prof Andrew Sindone AM

Prof Andrew Sindone AM

Managing Acute Heart Failure After Discharge: A Practical Guide for GPs

A/Prof Gino Pecoraro OAM

A/Prof Gino Pecoraro OAM

Oral Contraceptives on the PBS – A Practical Guide for GPs

Dr Terri Foran

Dr Terri Foran

The Impact of PFAS & Other Endocrine Disrupting Chemicals on Fertility

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.